VERU 112

Drug Profile

VERU 112

Alternative Names: VERU-112

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Veru Healthcare
  • Class Antigouts; Antirheumatics; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Familial Mediterranean fever; Gout

Most Recent Events

  • 03 Nov 2017 Early research in Familial Mediterranean fever in USA (PO) before November 2017 (Veru Healthcare pipeline, November 2017)
  • 03 Nov 2017 Early research in Gout in USA (PO) before November 2017 (Veru Healthcare pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top